世界中の市場調査レポートを販売!当社に無いレポートもお探しします。

レポートナンバー 0000037272

コンパニオン診断薬(CDx)市場レポート 2024-2034

Visiongain

Companion Diagnostics (CDx) Market Report 2024-2034

発刊日 2024/01/26

言語英語

体裁PDF/307ページ

ライセンス/価格307ページ

0000037272

Single - 1 Year License
(Team License - Up to 6 Users) - 1 Year License
Site
Enterprise

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※シングルユーザーライセンスのレポートは印刷不可、およびライセンス期間は1年となります。
※印刷可能のレポートをご希望の場合は、デパートメントライセンス(ライセンス期間1年、ユーザー数6人)をご検討ください。
※詳しくはお問い合わせください。

無料サンプル

  • サンプルはお問い合わせください。

レポート概要

製品・サービス別予測 (アッセイ、キット・試薬、ソフトウェア・サービス)、技術別 (ポリメラーゼ連鎖反応(PCR)、次世代シーケンシング(NGS)、in situハイブリダイゼーション(ISH)、免疫組織化学(IHC)、その他)、適応症別(がん、感染症、心血管疾患、神経疾患、その他)、エンドユーザー別(製薬・バイオ医薬品企業、レファレンスラボ、医薬品開発業務受託機関(CRO)、その他)、地域別・主要企業別国内市場分析、主要企業の分析、COVID-19の影響と回復パターン分析

CDx市場における技術改善

CDx市場は、主に技術開発のおかげで拡大しています。これらの開発によって、より優れた、より感度の高い、より焦点を絞ったCDx検査が実現しています。CDxの重要な技術開発には、次のようなものがあります。

  • 次世代シーケンシング(NGS):ハイスループットシーケンシング技術であるNGSを使用して、腫瘍ゲノム全体のシーケンシングを行うことができます。このデータを使用して、特定の薬剤が標的とできる遺伝子変異を特定することができます。
  • リキッドバイオプシー:循環中のがん細胞やその他の指標を特定できる侵襲性の低い手順は、リキッドバイオプシーです。この検査は、がんの経過と治療の有効性を追跡するために使用でき、従来の組織生検よりも侵襲性が低くなります。
  • AI(人工知能):AIは、膨大な量のCDxデータを分析できるコンピューターアルゴリズムを作成するために使用されています。この情報は、パターンを特定し、患者の転帰を予測するために利用できます。

レポート詳細

目次

1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Companion Diagnostics (CDx) Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2 Executive Summary

3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Increasing Rate of Chronic Illnesses
3.2.1.2 Technological Improvements in the CDx Market
3.2.1.3 Increasing Public Awareness of Personalised Medicine
3.2.1.4 Growing Need for Targeted Therapy
3.2.1.5 Rising Importance of Personalized Medicine
3.2.1.6 Increasing Global Incidence of Cancer
3.2.1.7 Growing Application Areas of Companion Diagnostics
3.2.2 Market Restraining Factors
3.2.2.1 Serious Issues and Substantial Medical Costs
3.2.2.2 Creating and Approving CDx Tests is a Challenging and Intricate Process.
3.2.2.3 High Capital Investment and Low Cost-benefit Ratio
3.2.2.4 Uncertain Reimbursement Scenario in Different Regions
3.2.2.5 High Cost of Immunotherapy Treatment
3.2.3 Market Opportunities
3.2.3.1 Creating New CDx Tests for Novel Targeted Medicines
3.2.3.2 Favourable Government Policies
3.2.3.3 Expansion into New Geographic Markets
3.2.3.4 Increasing Demand for Next-Generation Sequencing in CDx
3.2.3.5 Growing Significance of Companion Diagnostics in Drug Development
3.2.3.6 Higher Number of Clinical Trials
3.3 COVID-19 Impact Analysis
3.4 Porter Analysis
3.5 PEST Analysis

4 Companion Diagnostics (CDx) Market Analysis by Product & Services
4.1 Key Findings
4.2 Product & Services Segment: Market Attractiveness Index
4.3 Companion Diagnostics (CDx) Market Size Estimation and Forecast by Product & Services
4.4 Assays, Kits & Reagents
4.4.1 Market Size by Region, 2024-2034 (US$ Million)
4.4.2 Market Share by Region, 2024 & 2034 (%)
4.5 Software & Services
4.5.1 Market Size by Region, 2024-2034 (US$ Million)
4.5.2 Market Share by Region, 2024 & 2034 (%)

5 Companion Diagnostics (CDx) Market Analysis by Indication
5.1 Key Findings
5.2 Indication Segment: Market Attractiveness Index
5.3 Companion Diagnostics (CDx) Market Size Estimation and Forecast by Indication
5.4 Cancer
5.4.1 Market Size by Region, 2024-2034 (US$ Million)
5.4.2 Market Share by Region, 2024 & 2034 (%)
5.5 Infectious Disease
5.5.1 Market Size by Region, 2024-2034 (US$ Million)
5.5.2 Market Share by Region, 2024 & 2034 (%)
5.6 Cardiovascular Diseases
5.6.1 Market Size by Region, 2024-2034 (US$ Million)
5.6.2 Market Share by Region, 2024 & 2034 (%)
5.7 Neurological Diseases
5.7.1 Market Size by Region, 2024-2034 (US$ Million)
5.7.2 Market Share by Region, 2024 & 2034 (%)
5.8 Other Indications
5.8.1 Market Size by Region, 2024-2034 (US$ Million)
5.8.2 Market Share by Region, 2024 & 2034 (%)

6 Companion Diagnostics (CDx) Market Analysis by Technology
6.1 Key Findings
6.2 Technology Segment: Market Attractiveness Index
6.3 Companion Diagnostics (CDx) Market Size Estimation and Forecast by Technology
6.4 Polymerase Chain Reaction (PCR)
6.4.1 Market Size by Region, 2024-2034 (US$ Million)
6.4.2 Market Share by Region, 2024 & 2034 (%)
6.5 Next-Generation Sequencing (NGS)
6.5.1 Market Size by Region, 2024-2034 (US$ Million)
6.5.2 Market Share by Region, 2024 & 2034 (%)
6.6 In Situ Hybridization (ISH)
6.6.1 Market Size by Region, 2024-2034 (US$ Million)
6.6.2 Market Share by Region, 2024 & 2034 (%)
6.7 Immunohistochemistry (IHC)
6.7.1 Market Size by Region, 2024-2034 (US$ Million)
6.7.2 Market Share by Region, 2024 & 2034 (%)
6.8 Other Technologies
6.8.1 Market Size by Region, 2024-2034 (US$ Million)
6.8.2 Market Share by Region, 2024 & 2034 (%)

7 Companion Diagnostics (CDx) Market Analysis by End-users
7.1 Key Findings
7.2 End-users Segment: Market Attractiveness Index
7.3 Companion Diagnostics (CDx) Market Size Estimation and Forecast by End-users
7.4 Pharmaceutical & Biopharmaceutical Companies
7.4.1 Market Size by Region, 2024-2034 (US$ Million)
7.4.2 Market Share by Region, 2024 & 2034 (%)
7.5 Reference Laboratories
7.5.1 Market Size by Region, 2024-2034 (US$ Million)
7.5.2 Market Share by Region, 2024 & 2034 (%)
7.6 Contract Research Organizations (CROs)
7.6.1 Market Size by Region, 2024-2034 (US$ Million)
7.6.2 Market Share by Region, 2024 & 2034 (%)
7.7 Other End-users
7.7.1 Market Size by Region, 2024-2034 (US$ Million)
7.7.2 Market Share by Region, 2024 & 2034 (%)

8 Companion Diagnostics (CDx) Market Analysis by Region
8.1 Key Findings
8.2 Regional Market Size Estimation and Forecast

9 North America Companion Diagnostics (CDx) Market Analysis
9.1 Key Findings
9.2 North America Companion Diagnostics (CDx) Market Attractiveness Index
9.3 North America Companion Diagnostics (CDx) Market by Country, 2024, 2029 & 2034 (US$ Million)
9.4 North America Companion Diagnostics (CDx) Market Size Estimation and Forecast by Country
9.5 North America Companion Diagnostics (CDx) Market Size Estimation and Forecast by Product & Services
9.6 North America Companion Diagnostics (CDx) Market Size Estimation and Forecast by Indication
9.7 North America Companion Diagnostics (CDx) Market Size Estimation and Forecast by Technology
9.8 North America Companion Diagnostics (CDx) Market Size Estimation and Forecast by End-users
9.9 U.S. Companion Diagnostics (CDx) Market Analysis
9.10 Canada Companion Diagnostics (CDx) Market Analysis

10 Europe Companion Diagnostics (CDx) Market Analysis
10.1 Key Findings
10.2 Europe Companion Diagnostics (CDx) Market Attractiveness Index
10.3 Europe Companion Diagnostics (CDx) Market by Country, 2024, 2029 & 2034 (US$ Million)
10.4 Europe Companion Diagnostics (CDx) Market Size Estimation and Forecast by Country
10.5 Europe Companion Diagnostics (CDx) Market Size Estimation and Forecast by Product & Services
10.6 Europe Companion Diagnostics (CDx) Market Size Estimation and Forecast by Indication
10.7 Europe Companion Diagnostics (CDx) Market Size Estimation and Forecast by Technology
10.8 Europe Companion Diagnostics (CDx) Market Size Estimation and Forecast by End-users
10.9 Germany Companion Diagnostics (CDx) Market Analysis
10.10 UK Companion Diagnostics (CDx) Market Analysis
10.11 France Companion Diagnostics (CDx) Market Analysis
10.12 Italy Companion Diagnostics (CDx) Market Analysis
10.13 Spain Companion Diagnostics (CDx) Market Analysis
10.14 Rest of Europe Companion Diagnostics (CDx) Market Analysis

11 Asia Pacific Companion Diagnostics (CDx) Market Analysis
11.1 Key Findings
11.2 Asia Pacific Companion Diagnostics (CDx) Market Attractiveness Index
11.3 Asia Pacific Companion Diagnostics (CDx) Market by Country, 2024, 2029 & 2034 (US$ Million)
11.4 Asia Pacific Companion Diagnostics (CDx) Market Size Estimation and Forecast by Country
11.5 Asia Pacific Companion Diagnostics (CDx) Market Size Estimation and Forecast by Product & Services
11.6 Asia Pacific Companion Diagnostics (CDx) Market Size Estimation and Forecast by Indication
11.7 Asia Pacific Companion Diagnostics (CDx) Market Size Estimation and Forecast by Technology
11.8 Asia Pacific Companion Diagnostics (CDx) Market Size Estimation and Forecast by End-users
11.9 China Companion Diagnostics (CDx) Market Analysis
11.10 Japan Companion Diagnostics (CDx) Market Analysis
11.11 India Companion Diagnostics (CDx) Market Analysis
11.12 Australia Companion Diagnostics (CDx) Market Analysis
11.13 South Korea Companion Diagnostics (CDx) Market Analysis
11.14 Rest of Asia Pacific Companion Diagnostics (CDx) Market Analysis

12 Latin America Companion Diagnostics (CDx) Market Analysis
12.1 Key Findings
12.2 Latin America Companion Diagnostics (CDx) Market Attractiveness Index
12.3 Latin America Companion Diagnostics (CDx) Market by Country, 2024, 2029 & 2034 (US$ Million)
12.4 Latin America Companion Diagnostics (CDx) Market Size Estimation and Forecast by Country
12.5 Latin America Companion Diagnostics (CDx) Market Size Estimation and Forecast by Product & Services
12.6 Latin America Companion Diagnostics (CDx) Market Size Estimation and Forecast by Indication
12.7 Latin America Companion Diagnostics (CDx) Market Size Estimation and Forecast by Technology
12.8 Latin America Companion Diagnostics (CDx) Market Size Estimation and Forecast by End-users
12.9 Brazil Companion Diagnostics (CDx) Market Analysis
12.10 Mexico Companion Diagnostics (CDx) Market Analysis
12.11 Rest of Latin America Companion Diagnostics (CDx) Market Analysis

13 MEA Companion Diagnostics (CDx) Market Analysis
13.1 Key Findings
13.2 MEA Companion Diagnostics (CDx) Market Attractiveness Index
13.3 MEA Companion Diagnostics (CDx) Market by Country, 2024, 2029 & 2034 (US$ Million)
13.4 MEA Companion Diagnostics (CDx) Market Size Estimation and Forecast by Country
13.5 MEA Companion Diagnostics (CDx) Market Size Estimation and Forecast by Product & Services
13.6 MEA Companion Diagnostics (CDx) Market Size Estimation and Forecast by Indication
13.7 MEA Companion Diagnostics (CDx) Market Size Estimation and Forecast by Technology
13.8 MEA Companion Diagnostics (CDx) Market Size Estimation and Forecast by End-users
13.9 South Africa Companion Diagnostics (CDx) Market Analysis
13.10 GCC Companion Diagnostics (CDx) Market Analysis
13.11 Rest of MEA Companion Diagnostics (CDx) Market Analysis

14 Company Profiles
14.1 Strategic Outlook
14.2 F. Hoffmann-La Roche Ltd
14.2.1 Company Snapshot
14.2.2 Company Overview
14.2.3 Financial Analysis
14.2.3.1 Net Revenue, 2017-2022
14.2.3.2 R&D, 2017-2022
14.2.3.3 Regional Market Shares, 2022
14.2.4 Product Benchmarking
14.2.5 Strategic Outlook
14.3 Agilent Technologies, Inc.
14.3.1 Company Snapshot
14.3.2 Company Overview
14.3.3 Financial Analysis
14.3.3.1 Net Revenue, 2017-2022
14.3.3.2 R&D, 2017-2022
14.3.3.3 Regional Market Shares, 2022
14.3.4 Product Benchmarking
14.3.5 Strategic Outlook
14.4 QIAGEN
14.4.1 Company Snapshot
14.4.2 Company Overview
14.4.3 Financial Analysis
14.4.3.1 Net Revenue, 2017-2022
14.4.3.2 R&D, 2017-2022
14.4.3.3 Regional Market Shares, 2022
14.4.4 Product Benchmarking
14.5 Thermo Fisher Scientific Inc.
14.5.1 Company Snapshot
14.5.2 Company Overview
14.5.3 Financial Analysis
14.5.3.1 Net Revenue, 2017-2022
14.5.3.2 Regional Market Shares, 2022
14.5.4 Product Benchmarking
14.6 Abbott
14.6.1 Company Snapshot
14.6.2 Company Overview
14.6.3 Financial Analysis
14.6.3.1 Net Revenue, 2017-2022
14.6.3.2 R&D, 2017-2022
14.6.3.3 Regional Market Shares, 2022
14.6.4 Product Benchmarking
14.7 Almac Group
14.7.1 Company Snapshot
14.7.2 Company Overview
14.7.3 Product Benchmarking
14.7.4 Strategic Outlook
14.8 Danaher Corporation
14.8.1 Company Snapshot
14.8.2 Company Overview
14.8.3 Financial Analysis
14.8.3.1 Net Revenue, 2017-2022
14.8.3.2 Regional Market Shares, 2022
14.8.4 Product Benchmarking
14.9 Illumina, Inc.
14.9.1 Company Snapshot
14.9.2 Company Overview
14.9.3 Financial Analysis
14.9.3.1 Net Revenue, 2017-2022
14.9.3.2 R&D, 2017-2022
14.9.3.3 Regional Market Shares, 2022
14.9.4 Product Benchmarking
14.9.5 Strategic Outlook
14.10 bioMerieux
14.10.1 Company Snapshot
14.10.2 Company Overview
14.10.3 Financial Analysis
14.10.3.1 Net Revenue, 2017-2022
14.10.3.2 Regional Market Shares, 2022
14.10.4 Product Benchmarking
14.11 Myriad Genetics, Inc.
14.11.1 Company Snapshot
14.11.2 Company Overview
14.11.3 Financial Analysis
14.11.3.1 Net Revenue, 2017-2022
14.11.3.2 R&D, 2017-2022
14.11.3.3 Regional Market Shares, 2022
14.11.4 Product Benchmarking
14.12 Sysmex Corporation
14.12.1 Company Snapshot
14.12.2 Company Overview
14.12.3 Financial Analysis
14.12.3.1 Net Revenue, 2017-2022
14.12.3.2 R&D, 2017-2022
14.12.3.3 Regional Market Shares, 2022
14.12.4 Product Benchmarking
14.13 Guardant Health
14.13.1 Company Snapshot
14.13.2 Company Overview
14.13.3 Financial Analysis
14.13.3.1 Net Revenue, 2017-2022
14.13.3.2 R&D, 2017-2022
14.13.3.3 Regional Market Shares, 2022
14.13.4 Product Benchmarking

15 Conclusion and Recommendations
15.1 Concluding Remarks from Visiongain
15.2 Recommendations for Market Players

List of Tables
Table 1 Companion Diagnostics (CDx) Market Snapshot, 2024 & 2034 (US$ Million, AGR %)
Table 2 Companion Diagnostics (CDx) Market Forecast by Region, 2024-2034 (US$ Million, CAGR%): “V” Shaped Recovery
Table 3 Companion Diagnostics (CDx) Market Forecast by Region, 2024-2034 (US$ Million, CAGR%): “U” Shaped Recovery
Table 4 Companion Diagnostics (CDx) Market Forecast by Region, 2024-2034 (US$ Million, CAGR%): “W” Shaped Recovery
Table 5 Companion Diagnostics (CDx) Market Forecast by Region, 2024-2034 (US$ Million, CAGR%): “L” Shaped Recovery
Table 6 Companion Diagnostic Market Forecast by Product & Services, 2024-2034 (US$ Million, CAGR%)
Table 7 Assays, Kits & Reagents Segment Market Forecast by Region, 2024-2034 (US$ Million, CAGR%)
Table 8 Software & Services Segment Market Forecast by Region, 2024-2034 (US$ Million, CAGR%)
Table 9 Companion Diagnostic Market Forecast by Indication, 2024-2034 (US$ Million, CAGR%)
Table 10 Cancer Segment Market Forecast by Region, 2024-2034 (US$ Million, CAGR%)
Table 11 Infectious Disease Segment Market Forecast by Region, 2024-2034 (US$ Million, CAGR%)
Table 12 Cardiovascular Diseases Segment Market Forecast by Region, 2024-2034 (US$ Million, CAGR%)
Table 13 Neurological Diseases Segment Market Forecast by Region, 2024-2034 (US$ Million, CAGR%)
Table 14 Other Indications Segment Market Forecast by Region, 2024-2034 (US$ Million, CAGR%)
Table 15 Companion Diagnostic Market Forecast by Technology, 2024-2034 (US$ Million, CAGR%)
Table 16 PCR Segment Market Forecast by Region, 2024-2034 (US$ Million, CAGR%)
Table 17 Next-Generation Sequencing (NGS) Segment Market Forecast by Region, 2024-2034 (US$ Million, CAGR%)
Table 18 In Situ Hybridization (ISH) Segment Market Forecast by Region, 2024-2034 (US$ Million, CAGR%)
Table 19 Immunohistochemistry (IHC) Segment Market Forecast by Region, 2024-2034 (US$ Million, CAGR%)
Table 20 Other Technologies Segment Market Forecast by Region, 2024-2034 (US$ Million, CAGR%)
Table 21 Companion Diagnostic Market Forecast by End-users, 2024-2034 (US$ Million, CAGR%)
Table 22 Pharmaceutical & Biopharmaceutical Companies Segment Market Forecast by Region, 2024-2034 (US$ Million, CAGR%)
Table 23 Reference Laboratories Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 24 Contract Research Organizations (CROs) Segment Market Forecast by Region, 2024-2034 (US$ Million, CAGR%)
Table 25 Other End-users Segment Market Forecast by Region, 2024-2034 (US$ Million, CAGR%)
Table 26 Companion Diagnostics (CDx) Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Table 27 North America Companion Diagnostics (CDx) Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Table 28 North America Companion Diagnostics (CDx) Market Forecast by Product & Services, 2024-2034 (US$ Million, AGR %)
Table 29 North America Companion Diagnostics (CDx) Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
Table 30 North America Companion Diagnostics (CDx) Market Forecast by Technology, 2024-2034 (US$ Million, AGR %)
Table 31 North America Companion Diagnostics (CDx) Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
Table 32 U.S. Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Table 33 Canada Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Table 34 Europe Companion Diagnostics (CDx) Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Table 35 Europe Companion Diagnostics (CDx) Market Forecast by Product & Services, 2024-2034 (US$ Million, AGR %)
Table 36 Europe Companion Diagnostics (CDx) Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
Table 37 Europe Companion Diagnostics (CDx) Market Forecast by Technology, 2024-2034 (US$ Million, AGR %)
Table 38 Europe Companion Diagnostics (CDx) Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
Table 39 Germany Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Table 40 UK Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Table 41 France Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Table 42 Italy Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Table 43 Spain Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Table 44 Rest of Europe Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Table 45 Asia Pacific Companion Diagnostics (CDx) Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Table 46 Asia Pacific Companion Diagnostics (CDx) Market Forecast by Product & Services, 2024-2034 (US$ Million, AGR %)
Table 47 Asia Pacific Companion Diagnostics (CDx) Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
Table 48 Asia Pacific Companion Diagnostics (CDx) Market Forecast by Technology, 2024-2034 (US$ Million, AGR %)
Table 49 Asia Pacific Companion Diagnostics (CDx) Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
Table 50 China Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Table 51 Japan Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Table 52 India Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Table 53 Australia Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Table 54 South Korea Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Table 55 Rest of Asia Pacific Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Table 56 Latin America Companion Diagnostics (CDx) Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Table 57 Latin America Companion Diagnostics (CDx) Market Forecast by Product & Services, 2024-2034 (US$ Million, AGR %)
Table 58 Latin America Companion Diagnostics (CDx) Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
Table 59 Latin America Companion Diagnostics (CDx) Market Forecast by Technology, 2024-2034 (US$ Million, AGR %)
Table 60 Latin America Companion Diagnostics (CDx) Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
Table 61 Brazil Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Table 62 Mexico Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Table 63 Rest of Latin America Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Table 64 MEA Companion Diagnostics (CDx) Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Table 65 MEA Companion Diagnostics (CDx) Market Forecast by Product & Services, 2024-2034 (US$ Million, AGR %)
Table 66 MEA Companion Diagnostics (CDx) Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
Table 67 MEA Companion Diagnostics (CDx) Market Forecast by Technology, 2024-2034 (US$ Million, AGR %)
Table 68 MEA Companion Diagnostics (CDx) Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
Table 69 South Africa Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Table 70 GCC Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Table 71 Rest of MEA Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Table 72 Strategic Outlook
Table 73 F. Hoffmann-La Roche Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 74 F. Hoffmann-La Roche Ltd: Product Benchmarking
Table 75 F. Hoffmann-La Roche Ltd: Strategic Outlook
Table 76 Agilent Technologies, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 77 Agilent Technologies, Inc.: Product Benchmarking
Table 78 Agilent Technologies, Inc.: Strategic Outlook
Table 79 QIAGEN: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 80 QIAGEN: Product Benchmarking
Table 81 Thermo Fisher Scientific: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 82 Thermo Fisher Scientific.: Product Benchmarking
Table 83 Abbott: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 84 Abbott: Product Benchmarking
Table 85 Almac Group: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 86 Almac Group: Product Benchmarking
Table 87 Almac Group: Strategic Outlook
Table 88 Danaher Corporation: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 89 Danaher Corporation: Product Benchmarking
Table 90 Illumina: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 91 Illumina: Product Benchmarking
Table 92 Illumina: Strategic Outlook
Table 93 bioMerieux: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 94 Biomurieux: Product Benchmarking
Table 95 Myriad Genetics, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 96 MYRIAD GENETICS, INC.: Product Benchmarking
Table 97 Sysmex Corporation: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 98 Sysmex Corporation: Product Benchmarking
Table 99 Guardant Health: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 100 GUARDANT HEALTH: Product Benchmarking
?

List of Figures
Figure 1 Companion Diagnostics (CDx) Market Segmentation
Figure 2 Companion Diagnostics (CDx) Market by Technology: Market Attractiveness Index
Figure 3 Companion Diagnostics (CDx) Market by Indication: Market Attractiveness Index
Figure 4 Companion Diagnostics (CDx) Market by Product & Services: Market Attractiveness Index
Figure 5 Companion Diagnostics (CDx) Market by End-users: Market Attractiveness Index
Figure 6 Companion Diagnostics (CDx) Market Attractiveness Index by Region
Figure 7 Companion Diagnostics (CDx) Market: Market Dynamics
Figure 8 Companion Diagnostics (CDx) Market by Region, 2024-2034 (US$ Million, AGR %): “V” Shaped Recovery
Figure 9 Companion Diagnostics (CDx) Market by Region, 2024-2034 (US$ Million, AGR %): “U” Shaped Recovery
Figure 10 Companion Diagnostic Market by Region, 2024-2034 (US$ Million, AGR %): “W” Shaped Recovery
Figure 11 Companion Diagnostic Market by Region, 2024-2034 (US$ Million, AGR %): “L” Shaped Recovery
Figure 12 PEST Analysis of Companion Diagnostic Market
Figure 13 Companion Diagnostics (CDx) Market by Product & Services: Market Attractiveness Index
Figure 14 Companion Diagnostics (CDx) Market Forecast by Product & Services, 2024-2034 (US$ Million, AGR %)
Figure 15 Companion Diagnostics (CDx) Market Share Forecast by Product & Services, 2024, 2029, 2034 (%)
Figure 16 Assays, Kits & Reagents Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 17 Assays, Kits & Reagents Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 18 Software & Services Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 19 Software & Services Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 20 Companion Diagnostics (CDx) Market by Indication: Market Attractiveness Index
Figure 21 Companion Diagnostics (CDx) Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
Figure 22 Companion Diagnostics (CDx) Market Share Forecast by Indication, 2024, 2029, 2034 (%)
Figure 23 Cancer Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 24 Cancer Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 25 Infectious Disease Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 26 Infectious Disease Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 27 Cardiovascular Diseases Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 28 Cardiovascular Diseases Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 29 Neurological Diseases Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 30 Neurological Diseases Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 31 Other Indications Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 32 Other Indications Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 33 Companion Diagnostics (CDx) Market by Technology: Market Attractiveness Index
Figure 34 Companion Diagnostics (CDx) Market Forecast by Technology, 2024-2034 (US$ Million, AGR %)
Figure 35 Companion Diagnostics (CDx) Market Share Forecast by Technology, 2024, 2029, 2034 (%)
Figure 36 Polymerase Chain Reaction (PCR) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 37 Polymerase Chain Reaction (PCR) Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 38 Next-Generation Sequencing (NGS) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 39 Next-Generation Sequencing (NGS) Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 40 In Situ Hybridization (ISH) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 41 In Situ Hybridization (ISH) Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 42 Immunohistochemistry (IHC) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 43 Immunohistochemistry (IHC) Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 44 Other Technologies Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 45 Other Technologies Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 46 Companion Diagnostics (CDx) Market by End-users: Market Attractiveness Index
Figure 47 Companion Diagnostics (CDx) Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
Figure 48 Companion Diagnostics (CDx) Market Share Forecast by End-users, 2024, 2029, 2034 (%)
Figure 49 Pharmaceutical & Biopharmaceutical Companies Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 50 Pharmaceutical & Biopharmaceutical Companies Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 51 Reference Laboratories Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 52 Reference Laboratories Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 53 Contract Research Organizations (CROs) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 54 Contract Research Organizations (CROs) Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 55 Other End-users Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 56 Other End-users Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 57 Companion Diagnostics (CDx) Market Forecast by Region 2024 and 2034 (Revenue, CAGR%)
Figure 58 Companion Diagnostics (CDx) Market Share Forecast by Region 2024, 2029, 2034 (%)
Figure 59 Companion Diagnostics (CDx) Market by Region, 2024-2034 (US$ Million, AGR %)
Figure 60 North America Companion Diagnostics (CDx) Market Attractiveness Index
Figure 61 North America Companion Diagnostics (CDx) Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 62 North America Companion Diagnostics (CDx) Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 63 North America Companion Diagnostics (CDx) Market Share Forecast by Country, 2024 & 2034 (%)
Figure 64 North America Companion Diagnostics (CDx) Market Forecast by Product & Services, 2024-2034 (US$ Million, AGR %)
Figure 65 North America Companion Diagnostics (CDx) Market Share Forecast by Product & Services, 2024 & 2034 (%)
Figure 66 North America Companion Diagnostics (CDx) Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
Figure 67 North America Companion Diagnostics (CDx) Market Share Forecast by Indication, 2024 & 2034 (%)
Figure 68 North America Companion Diagnostics (CDx) Market Forecast by Technology, 2024-2034 (US$ Million, AGR %)
Figure 69 North America Companion Diagnostics (CDx) Market Share Forecast by Technology, 2024 & 2034 (%)
Figure 70 North America Companion Diagnostics (CDx) Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
Figure 71 North America Companion Diagnostics (CDx) Market Share Forecast by End-users, 2024 & 2034 (%)
Figure 72 U.S. Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 73 Canada Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 74 Europe Companion Diagnostics (CDx) Market Attractiveness Index
Figure 75 Europe Companion Diagnostics (CDx) Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 76 Europe Companion Diagnostics (CDx) Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 77 Europe Companion Diagnostics (CDx) Market Share Forecast by Country, 2024 & 2034 (%)
Figure 78 Europe Companion Diagnostics (CDx) Market Forecast by Product & Services, 2024-2034 (US$ Million, AGR %)
Figure 79 Europe Companion Diagnostics (CDx) Market Share Forecast by Product & Services, 2024 & 2034 (%)
Figure 80 Europe Companion Diagnostics (CDx) Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
Figure 81 Europe Companion Diagnostics (CDx) Market Share Forecast by Indication, 2024 & 2034 (%)
Figure 82 Europe Companion Diagnostics (CDx) Market Forecast by Technology, 2024-2034 (US$ Million, AGR %)
Figure 83 Europe Companion Diagnostics (CDx) Market Share Forecast by Technology, 2024 & 2034 (%)
Figure 84 Europe Companion Diagnostics (CDx) Market Forecast by End-user, 2024-2034 (US$ Million, AGR %)
Figure 85 Europe Companion Diagnostics (CDx) Market Share Forecast by End-user, 2024 & 2034 (%)
Figure 86 Germany Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 87 UK Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 88 France Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 89 Italy Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 90 Spain Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 91 Rest of Europe Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 92 Asia Pacific Companion Diagnostics (CDx) Market Attractiveness Index
Figure 93 Asia Pacific Companion Diagnostics (CDx) Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 94 Asia Pacific Companion Diagnostics (CDx) Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 95 Asia Pacific Companion Diagnostics (CDx) Market Share Forecast by Country, 2024 & 2034 (%)
Figure 96 Asia Pacific Companion Diagnostics (CDx) Market Forecast by Product & Services, 2024-2034 (US$ Million, AGR %)
Figure 97 Asia Pacific Companion Diagnostics (CDx) Market Share Forecast by Product & Services, 2024 & 2034 (%)
Figure 98 Asia Pacific Companion Diagnostics (CDx) Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
Figure 99 Asia Pacific Companion Diagnostics (CDx) Market Share Forecast by Indication, 2024 & 2034 (%)
Figure 100 Asia Pacific Companion Diagnostics (CDx) Market Forecast by Technology, 2024-2034 (US$ Million, AGR %)
Figure 101 Asia Pacific Companion Diagnostics (CDx) Market Share Forecast by Technology, 2024 & 2034 (%)
Figure 102 Asia Pacific Companion Diagnostics (CDx) Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
Figure 103 Asia Pacific Companion Diagnostics (CDx) Market Share Forecast by End-users, 2024 & 2034 (%)
Figure 104 China Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 105 Japan Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 106 India Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 107 Australia Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 108 South Korea Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 109 Rest of Asia Pacific Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 110 Latin America Companion Diagnostics (CDx) Market Attractiveness Index
Figure 111 Latin America Companion Diagnostics (CDx) Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 112 Latin America Companion Diagnostics (CDx) Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 113 Latin America Companion Diagnostics (CDx) Market Share Forecast by Country, 2024 & 2034 (%)
Figure 114 Latin America Companion Diagnostics (CDx) Market Forecast by Product & Services, 2024-2034 (US$ Million, AGR %)
Figure 115 Latin America Companion Diagnostics (CDx) Market Share Forecast by Product & Services, 2024 & 2034 (%)
Figure 116 Latin America Companion Diagnostics (CDx) Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
Figure 117 Latin America Companion Diagnostics (CDx) Market Share Forecast by Indication, 2024 & 2034 (%)
Figure 118 Latin America Companion Diagnostics (CDx) Market Forecast by Technology, 2024-2034 (US$ Million, AGR %)
Figure 119 Latin America Companion Diagnostics (CDx) Market Share Forecast by Technology, 2024 & 2034 (%)
Figure 120 Latin America Companion Diagnostics (CDx) Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
Figure 121 Latin America Companion Diagnostics (CDx) Market Share Forecast by End-users, 2024 & 2034 (%)
Figure 122 Brazil Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 123 Mexico Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 124 Rest of Latin America Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 125 MEA Companion Diagnostics (CDx) Market Attractiveness Index
Figure 126 MEA Companion Diagnostics (CDx) Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 127 MEA Companion Diagnostics (CDx) Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 128 MEA Companion Diagnostics (CDx) Market Share Forecast by Country, 2024 & 2034 (%)
Figure 129 MEA Companion Diagnostics (CDx) Market Forecast by Product & Services, 2024-2034 (US$ Million, AGR %)
Figure 130 MEA Companion Diagnostics (CDx) Market Share Forecast by Product & Services, 2024 & 2034 (%)
Figure 131 MEA Companion Diagnostics (CDx) Market Forecast by Indication, 2024-2034 (US$ Million, AGR %)
Figure 132 MEA Companion Diagnostics (CDx) Market Share Forecast by Indication, 2024 & 2034 (%)
Figure 133 MEA Companion Diagnostics (CDx) Market Forecast by Technology, 2024-2034 (US$ Million, AGR %)
Figure 134 MEA Companion Diagnostics (CDx) Market Share Forecast by Technology, 2024 & 2034 (%)
Figure 135 MEA Companion Diagnostics (CDx) Market Forecast by End-users, 2024-2034 (US$ Million, AGR %)
Figure 136 MEA Companion Diagnostics (CDx) Market Share Forecast by End-users, 2024 & 2034 (%)
Figure 137 South Africa Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 138 GCC Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 139 Rest of MEA Companion Diagnostics (CDx) Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 140 F. Hoffmann-La Roche Ltd: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 141 F. Hoffmann-La Roche Ltd: R&D, 2017-2022 (US$ Million, AGR%)
Figure 142 F. Hoffmann-La Roche Ltd: Regional Market Shares, 2022
Figure 143 Agilent Technologies, Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 144 Agilent Technologies, Inc.: R&D, 2017-2022 (US$ Million, AGR%)
Figure 145 Agilent Technologies, Inc.: Regional Market Shares, 2022
Figure 146 QIAGEN: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 147 QIAGEN: R&D, 2017-2022 (US$ Million, AGR%)
Figure 148 QIAGEN: Regional Market Shares, 2022
Figure 149 Thermo Fisher Scientific: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 150 Thermo Fisher Scientific.: Regional Market Shares, 2022
Figure 151 Abbott: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 152 Abbott: R&D, 2017-2022 (US$ Million, AGR%)
Figure 153 Abbott: Regional Market Shares, 2022
Figure 154 Danaher Corporation: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 155 Danaher Corporation: Regional Market Shares, 2022
Figure 156 Illumina: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 157 Illumina: R&D, 2017-2022 (US$ Million, AGR%)
Figure 158 Illumina: Regional Market Shares, 2022
Figure 159 bioMerieux: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 160 bioMerieux: Regional Market Shares, 2022
Figure 161 Myriad Genetics, Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 162 Myriad Genetics, Inc.: R&D, 2017-2022 (US$ Million, AGR%)
Figure 163 Myriad Genetics, Inc.: Regional Market Shares, 2022
Figure 164 Sysmex Corp: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 165 Sysmex Corp: R&D, 2017-2022 (US$ Million, AGR%)
Figure 166 Sysmex Corp: Regional Market Shares, 2022
Figure 167 Guardant Health: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 168 Guardant Health: R&D, 2017-2022 (US$ Million, AGR%)
Figure 169 GUARDANT HEALTH, INC: Regional Market Shares, 2022

この商品のレポートナンバー

0000037272

TOP